Biogen Inc. $BIIB Stock Holdings Increased by Swiss National Bank

Swiss National Bank increased its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 7.2% in the 1st quarter, HoldingsChannel.com reports. The firm owned 430,600 shares of the biotechnology company’s stock after buying an additional 28,800 shares during the quarter. Swiss National Bank’s holdings in Biogen were worth $78,942,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BIIB. Empowered Funds LLC increased its stake in Biogen by 64.9% in the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock valued at $965,000 after buying an additional 2,777 shares during the period. Focus Partners Wealth boosted its stake in shares of Biogen by 172.2% during the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after buying an additional 6,436 shares during the period. Sivia Capital Partners LLC acquired a new stake in shares of Biogen during the 2nd quarter valued at $216,000. Cerity Partners LLC grew its holdings in shares of Biogen by 15.3% during the 2nd quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company’s stock valued at $5,847,000 after acquiring an additional 6,184 shares in the last quarter. Finally, NewEdge Advisors LLC grew its holdings in shares of Biogen by 13.4% during the 2nd quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company’s stock valued at $336,000 after acquiring an additional 316 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Stock Up 1.6%

Biogen stock opened at $203.16 on Wednesday. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 1-year low of $123.38 and a 1-year high of $219.72. The firm’s fifty day simple moving average is $199.55 and its 200-day simple moving average is $189.45. The company has a market capitalization of $29.99 billion, a P/E ratio of 21.80 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The firm had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. Biogen’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the prior year, the company posted $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Sell-side analysts forecast that Biogen Inc. will post 13.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on BIIB shares. The Goldman Sachs Group increased their price objective on Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Royal Bank Of Canada boosted their target price on Biogen from $227.00 to $242.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Evercore assumed coverage on Biogen in a research report on Friday, May 15th. They issued an “outperform” rating on the stock. Zacks Research downgraded Biogen from a “hold” rating to a “strong sell” rating in a research note on Monday, June 29th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Biogen in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Biogen currently has an average rating of “Moderate Buy” and an average price target of $220.57.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.